Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma

Next Previous
Search
Trial Profile

Phase Ib Study of Gevokizumab in Combination With Standard of Care Anti-cancer Therapies in Patients With Metastatic Colorectal Cancer, Gastroesophageal Cancer and Renal Cell Carcinoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gevokizumab (Primary) ; Bevacizumab; Cabozantinib; Fluorouracil; Folinic acid; Irinotecan; Levofolinic acid; Oxaliplatin; Paclitaxel; Ramucirumab
  • Indications Colorectal cancer; Gastric cancer; Oesophageal cancer; Renal cell carcinoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 07 Mar 2025 Status changed from active, no longer recruiting to completed.
    • 07 Jan 2025 Planned End Date changed from 10 Feb 2025 to 9 Feb 2025.
    • 27 Nov 2024 Planned End Date changed from 29 Jan 2025 to 10 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top